MedTrace Logo

A Phase 2b Diabetic Kidney Disease Study

NCT04170543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 609

Last updated 2024-07-10

Study results available
· View outcomes & findings →

Summary

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

Conditions

  • Diabetic Kidney Disease

Interventions

DRUG

MEDI3506

Dose 1, Dose 2, Dose 3, Dose 4

DRUG

Placebo

Placebo

DRUG

Dapagliflozin

Dapagliflozin 10 mg

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
101 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2023-05-16
Completion
2023-05-16
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • Chile
  • Japan
  • Peru
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170543 on ClinicalTrials.gov